Genmab — December 2017
-
Kommer vel an på hvornår (hvis) man får godkendelsen til 1. linie.
-
BUZZ-Genmab falls after rivals steals limelight at key cancer conference - Reuters News
12-Dec-2017 10:01:54
** Biotech Genmab GEN.CO shares slump more than 7 percent after the firm provided an update on its research and development strategy during the American Society of Hematology meeting in Atlanta, a key cancer conference
** "We think it should rise on what was announced yesterday but we think that it is the rising cost base which some has perceived as negative," Jyske Bank trader Martin Mun -
Munk says
** Genmab expects its expenses to grow 40-50 pct next year (Full Story)
** Sydbank analyst Soren Lontoft highlights the competition from rival Bluebird BLUE.O as the reason for the share drop
** "I think the investors react to the fact that there are some of these competitors who steal the limelight with some really strong results"
** Bluebird experimental gene-modifying immunotherapy drug, bb2121, co-developed with Celgene CELG.O, received positive responses in early stage myeloma s -
study, the firm said during the ASH meeting (
-
Ja, sådan forstår jeg det også
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind